[1]毛心仪,姚峥嵘.制度创新理论视角下我国药品研发制度变迁设计[J].卫生经济研究,2021,38(7):38-43.
MAO Xin-yi,YAO Zheng-rong.Institutional Change Design of Drug Research and Development in China from the Perspective of Institutional Innovation Theory[J].Journal Press of Health Economics Research,2021,38(7):38-43.
点击复制
制度创新理论视角下我国药品研发制度变迁设计
卫生经济研究[ISSN:1004-7778/CN:33-1056/F]
- 卷:
-
38
- 期数:
-
2021年7期
- 页码:
-
38-43
- 栏目:
-
药械管理
- 出版日期:
-
2021-06-30
文章信息/Info
- Title:
-
Institutional Change Design of Drug Research and Development in China from the Perspective of Institutional Innovation Theory
- 作者:
-
毛心仪1; 姚峥嵘1
-
1.南京中医药大学卫生经济管理学院，江苏 南京 210023
- Author(s):
-
MAO Xin-yi; YAO Zheng-rong
-
School of Health Economics and Management, Nanjing University of Traditional Chinese Medicine, Nanjing Jiangsu 210023, China
-
- 关键词:
-
药品研发; 制度创新理论; 制度变迁
- Keywords:
-
drug research and development; institutional innovation theory; institutional change
- 分类号:
-
R19
- 文献标志码:
-
A
- 摘要:
-
药品研发是保证新药可及性和药品质量的关键。本文基于制度创新理论，总结药品研发的投入产出情况，针对药品研发外部激励制度不均衡和内部治理制度不均衡问题，提出强制性制度变迁和诱致性制度变迁的设计建议，促进药品研发制度达到均衡状态。
- Abstract:
-
Drug research and development are the key to ensure accessibility and quality of new drugs. Based on the theory of institutional innovation, this paper summarizes the input and output of drug research and development, and aiming at the imbalance of external incentive system and internal governance system of drug research and development, puts forward the design suggestions of compulsory institutional change and induced institutional change to promote the equilibrium state of drug research and development system.
参考文献/References:
[1] （美）科斯，等著；刘守英，等译.财产权利与制度变迁：产权学派与新制度学派译文集[M].上海：三联书店上海分店，1991：373-384.
[2] 白育庭，袁尚会，刘伟华.制度创新理论视阈下的地方高校辅导员专业化建设探究[J].湖北科技学院学报，2019，39（2）：110-115.
[3] 范微，熊季霞.基于制度创新理论提高公立医院综合绩效的治理制度变迁设计[J].中国卫生事业管理，2017，34（2）：81-82，127.
[4] 刘旭宁.买方垄断、药品定价与我国制药产业研发投入[D].山东大学，2012.
[5] 赵娜娜，孙利华.中国医药产业新药研发能力研究[J].中国医药工业杂志，2018，49（9）：1321-1326.
[6] 国家统计局.中国高技术产业统计年鉴[M].北京：中国统计出版社，2010-2017+2019.
[7] 关晓静总编.中国科技统计年鉴[M].北京：中国统计出版社，2018.
[8] 关晓静总编.中国科技统计年鉴[M].北京：中国统计出版社，2019.
[9] Evaluate Pharma.World Preview 2019,Outlook to 2024[EB/OL].(2019-06-04)[2021-01-07].https://info.evaluate.com/rs/607-YGS-364/images/EvaluatePharma_World_Preview_2019.pdf.
[10] FDA.Novel Drug Approvals for 2015[EB/OL].(2019-11-15)[ 2021-01-07].https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2015.
[11] FDA.Novel Drug Approvals for 2016[EB/OL].(2019-11-15)[ 2021-01-07].https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2016.
[12] FDA.Novel Drug Approvals for 2017[EB/OL].(2019-11-15)[ 2021-01-07].https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017.
[13] FDA.Novel Drug Approvals for 2018[EB/OL].(2019-11-15)[ 2021-01-07].https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018.
[14] FDA.Novel Drug Approvals for 2019[EB/OL].(2019-11-15)[ 2021-01-07].https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019.
[15] FDA.Novel Drug Approvals for 2020[EB/OL].(2019-11-15)[ 2021-01-07]. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020.
[16] EFPIA.The Pharmaceutical Industry in Figures Key Data 2020 [EB/OL].(2019-12-31)[2021-01-07].https://www.efpia.eu/media/554521/efpia_pharmafigures_2020_web.pdf.
[17] Njardarson Group(The University of Arizona).Top 200 Pharmaceuticals by Retail Sales in 2019[EB/OL].( 2020-05-04)[ 2020-11-20].https://njardarson.lab.arizona.edu/content/top-pharmaceuticals-poster.
[18] 姚雪芳，丁锦希，李鹏辉，等.国外新药特殊审评模式比较与借鉴[J].中国药学杂志，2016，51（19）：1714-1720.
[19] 丁锦希，李苏菊，姚雪芳，等.我国新药优先审评模式研究[J].中国新药杂志，2017，26（8）：872-877.
[20] 郭熙保，龚广祥.属地经营、市场扩张和企业创新——来自中国制造业数据的证据[J].山东大学学报（哲学社会科学版），2020（1）：70-91.
[21] PharmExec.Pharm Exec's Top 50 Companies 2018 [EB/OL].(2018-01-01)[ 2019-05-24].http://www.cpa.org.cn/?do=info&cid=74800.
[22] 药智报告.2018药企研发实力抢先看，上亿研发投入是基本？[EB/OL].（2018-04-08）[2019-04-28].https://news.yaozh.com/archive/22288.html.
更新日期/Last Update:
2021-06-30